On Thursday, the Texan Representatives House-passed reforms to largely expand the area’s clinical cannabis program and decriminalize cannabis possession.
These are the most recent advancements coming during a week that has been flooded with the approval of multiple bills within the chamber, such as various initiatives to minimize punishments for marijuana concentrates possession and mandate the Texas government to research the potential therapeutic properties of psychedelics like MDMA and psilocybin.
The reform to decriminalize possession of not more than an ounce of marijuana was advanced during the chamber’s second reading through a voice vote.
The bill was sponsored by Representative Erin Zwiener and would end the risk of being apprehended for small amounts of the substance and give folks a chance to keep off conviction through the provision of dismissals and referrals. The final vote during the chamber’s 3rd reading is still necessary to officially put the reform before the Senate.
Although the House passed a marijuana decriminalization reform two years ago, it failed to ascend past the Senate.
The different clinical marijuana expansion reform was finally approved in the House through a 134-12 ballot vote. It would include chronic pain, cancer, and PTSD (post-traumatic stress disorder) as ailments that make individuals eligible for the territory’s limited clinical marijuana program. The reform was passed early this month in the House Public Health Committee.
The reform would additionally allow the State Health Services Department to add other qualifying conditions through administrative rulemaking. It also would also increase the THC limit for clinical cannabis commodities to 5% from the previous 0.5%.
Although activists have applauded Texan legislators for making efforts to upgrade the territory’s current programs, they feel that it can still be improved and expect changes that enable more individuals to access marijuana when it appears in the Senate.